Sino BiopharmaceuticalSBMFF -1.48%61 PB Ratio is 2.44 as of Jul. 03, 2026, which is 53% below its 10-year median of 5.17. GuruFocus rates SBMFF with a GF Score™ of 61/100 and a GF Value™ of $0.60 (Fairly Valued). The stock has 4 warning signs investors should review. Among 1,228 Biotechnology companies, Sino Biopharmaceutical ranks better than 57.08% on this metric.
Sino Biopharmaceutical Ltd stock PB Ratio (=2.49) is close to 1-year low of 2.25.
The historical rank and industry rank for Sino Biopharmaceutical's PB Ratio or its related term are showing as below:
SBMFF'
s PB Ratio Range Over the Past 10 Years
Min: 1.29 Med: 5.17 Max: 13.22
Current: 2.49
During the past 13 years, Sino Biopharmaceutical's highest PB Ratio was 13.22. The lowest was 1.29. And the median was 5.17.
SBMFF's PB Ratio is ranked better than 57.08% of 1228
companies
in the Biotechnology industry
Industry Median: 2.97
vs SBMFF: 2.49
During the past 12 months, Sino Biopharmaceutical's average Book Value Per Share Growth Rate was -0.50% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 1.70% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 8.50% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was 17.40% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Sino Biopharmaceutical was 75.30% per year. The lowest was -30.70% per year. And the median was 18.20% per year.
Back to Basics: PB Ratio
Sino Biopharmaceutical (OTCPK:SBMFF) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Sino Biopharmaceutical's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sino Biopharmaceutical PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Sino Biopharmaceutical's PB Ratio distribution charts can be found below:
* The bar in red indicates where Sino Biopharmaceutical's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Sino Biopharmaceutical (SBMFF) has a PB Ratio of 2.44 as of Jul. 03, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Sino Biopharmaceutical and its competitors. This is 53% below median its historical median of 5.17. Over the past decade, Sino Biopharmaceutical's PB Ratio has ranged from 1.29 to 13.22. According to the industry distribution chart, Sino Biopharmaceutical ranks #527 out of 1228 companies in the Biotechnology industry, placing it in the top 42.9%.
Is Sino Biopharmaceutical's PB Ratio too high?
Sino Biopharmaceutical's current PB Ratio of 2.44 is 53% below median its 10-year median of 5.17. Over the past 10 years, this metric has ranged from a low of 1.29 to a high of 13.22. The Biotechnology industry median PB Ratio is 2.97. Sino Biopharmaceutical's value of 2.44 is 17.8% below this industry median. Based on the distribution chart, Sino Biopharmaceutical ranks #527 out of 1228 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Sino Biopharmaceutical has a GF Score™ of 61/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Sino Biopharmaceutical's PB Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Sino Biopharmaceutical ranks #527 out of 1228 companies for PB Ratio. This puts Sino Biopharmaceutical in the upper half of its industry. The industry median PB Ratio is 2.97. Sino Biopharmaceutical's value of 2.44 is 17.8% below this benchmark. Historically, Sino Biopharmaceutical's own PB Ratio has ranged from 1.29 to 13.22 over the past decade. While the company's 10-year median is 5.17 vs. the industry median of 2.97, Sino Biopharmaceutical has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.97, based on 1,228 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sino Biopharmaceutical's current PB Ratio of 2.44 is 17.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Sino Biopharmaceutical and its competitors. For the Biotechnology industry, the median PB Ratio is 2.97 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sino Biopharmaceutical's current PB Ratio is 2.44, which is 53% below median its own 10-year median of 5.17. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sino Biopharmaceutical stock overvalued right now?
Based on GuruFocus' analysis, Sino Biopharmaceutical (SBMFF) is currently considered Fairly Valued. The stock's GF Value™ is $0.60, compared to a current price of $0.59 — trading 1.2% below its estimated fair value. The current PB Ratio is 2.44, which is 53% below median its 10-year median of 5.17 and 17.8% below the Biotechnology industry median of 2.97. Sino Biopharmaceutical's overall GF Score™ is 61/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Sino Biopharmaceutical (SBMFF), the current PB Ratio is 2.44 as of Jul. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sino Biopharmaceutical (SBMFF) Overvalued in 2026?
Based on GuruFocus' analysis, Sino Biopharmaceutical stock appears to be undervalued.
The current stock price of $0.59 is trading 1.2% below its estimated GF Value™ of $0.60.
GuruFocus considers Sino Biopharmaceutical to be Fairly Valued.
Key valuation signals for SBMFF:
PB Ratio: 2.44 (53% below median its 10-year median of 5.17)
GF Value™: $0.60 vs. price of $0.59 (1.2% below fair value)
Industry Position: 17.8% below the Biotechnology median (#527 of 1228)
No single metric tells the full story. See the SBMFF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sino Biopharmaceutical Ltd is an investment holding company. The company and its subsidiaries are principally engaged in the research and development, production and sale of a series of pharmaceutical products. Its business covering the entire industrial chain of R&D, production and commercialization of drugs, biological products and high-end generic drugs. The company's therapeutic areas include: oncology, liver disease, respiratory, and surgery/pain relief. The company's revenue was generated from the sale of pharmaceutical products in the Chinese mainland.
61GF Score
Get the complete analysis for SBMFF
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SBMFF has been successfully added to your 
